IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) in HLA-A*02+ patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2).

Sandra P. DAngelo,Jonathan Christopher Noujaim,Fiona C. Thistlethwaite,Albiruni Ryan Abdul Razak,Silvia Stacchiotti,Warren Chow,John B. A. G. Haanen,Anna Weinberg Chalmers,Steven I. Robinson,Brian A. Van Tine,Kristen N. Ganjoo,Melissa Lynne Johnson,Victoria L. Chiou,Faitg Thomas H,Mary Woessner,Laura Pearce,Aiman Shalabi,Jean-Yves Blay,George D. Demetri

IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) in HLA-A*02+ patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2).

2021

Sandra P. DAngelo
Jonathan Christopher Noujaim
Fiona C. Thistlethwaite
Albiruni Ryan Abdul Razak
Silvia Stacchiotti
Warren Chow
John B. A. G. Haanen
Anna Weinberg Chalmers
Steven I. Robinson
Brian A. Van Tine
Kristen N. Ganjoo
Melissa Lynne Johnson
Victoria L. Chiou
Faitg Thomas H
Mary Woessner
Laura Pearce
Aiman Shalabi
Jean-Yves Blay
George D. Demetri

TPS11582Background: Letetresgene autoleucel (lete-cel; GSK3377794) is an autologous T-cell product using a genetically modified T-cell receptor to target cancer cells expressing the cancer testis a...

Keywords:

Cancer research
testis cancer
Medicine
Synovial sarcoma
Genetically modified organism
HLA-A
Receptor
Cancer cell
Myxoid/Round Cell Liposarcoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations